



# The inhibitory role of purinergic P2Y receptor on $Mg^{2+}$ transport across intestinal epithelium-like Caco-2 monolayer

Narongrit Thongon<sup>1</sup> · Siriporn Chamniansawat<sup>2</sup>

Received: 31 March 2018 / Accepted: 13 July 2018 / Published online: 21 July 2018  
© The Physiological Society of Japan and Springer Japan KK, part of Springer Nature 2018

## Abstract

The mechanism of proton pump inhibitors (PPIs) suppressing intestinal  $Mg^{2+}$  uptake is unknown. The present study aimed to investigate the role of purinergic P2Y receptors in the regulation of  $Mg^{2+}$  absorption in normal and omeprazole-treated intestinal epithelium-like Caco-2 monolayers. Omeprazole suppressed  $Mg^{2+}$  transport across Caco-2 monolayers. An agonist of the P2Y<sub>2</sub> receptor, but not the P2Y<sub>4</sub> or P2Y<sub>6</sub> receptor, suppressed  $Mg^{2+}$  transport across control and omeprazole-treated monolayers. Omeprazole enhanced P2Y<sub>2</sub> receptor expression in Caco-2 cells. Forskolin and P2Y<sub>2</sub> receptor agonist markedly enhanced apical  $HCO_3^-$  secretion by control and omeprazole-treated monolayers. The P2Y<sub>2</sub> receptor agonist suppressed  $Mg^{2+}$  transport and stimulated apical  $HCO_3^-$  secretion through the G<sub>q</sub>-protein coupled-phospholipase C (PLC) dependent pathway. Antagonists of cystic fibrosis transmembrane conductance regulator (CFTR) and Na<sup>+</sup>-HCO<sub>3</sub><sup>-</sup> cotransporter-1 (NBCe1) could nullify the inhibitory effect of P2Y<sub>2</sub> receptor agonist on  $Mg^{2+}$  transport across control and omeprazole-treated Caco-2 monolayers. Our results propose an inhibitory role of P2Y<sub>2</sub> on intestinal  $Mg^{2+}$  absorption.

**Keywords** Caco-2 monolayers · Intestinal  $HCO_3^-$  secretion ·  $Mg^{2+}$  absorption · Proton pump inhibitor · P2Y<sub>2</sub> receptor

## Introduction

Although there is an abundant amount of magnesium ( $Mg^{2+}$ ) within human cells, and it has vital roles in numerous biological functions [1], knowledge regarding regulatory mechanisms of  $Mg^{2+}$  homeostasis is still minimal. Theoretically, plasma  $Mg^{2+}$  level is regulated within a narrow range by the synergistic actions of intestinal absorption, bone and soft tissue storage, and renal excretion [1]. Since dietary intake is the only source of  $Mg^{2+}$ , intestinal absorption is vital for normal  $Mg^{2+}$  homeostasis. However, the understanding of

the regulatory mechanism of intestinal  $Mg^{2+}$  absorption is still elusive. Principally, enterocyte epithelium absorbs  $Mg^{2+}$  via both saturable transcellular and non-saturable paracellular transport [1]. Approximately 90% of total intestinal  $Mg^{2+}$  uptake is processed through a  $Mg^{2+}$  channel-independent paracellular passive mechanism which exclusively occurs in the small intestine [1–3]. The  $Mg^{2+}$  channel-dependent transcellular active  $Mg^{2+}$  uptake plays an important role during low dietary  $Mg^{2+}$  intake [3].

In the small intestine, enterocyte epithelial cells are equipped with acid sensors, e.g., acid-sensing ion channel (ASIC), ovarian cancer G protein-coupled receptor 1 (OGR1), and transient receptor potential vanilloid (TRPV) that are implicated in mucosal defense by detecting mucosal protons and stimulating mucosal  $HCO_3^-$  secretion [4–9]. In addition to this mucosal defense, intestinal acid sensors also regulate ion transport across the enterocyte epithelium. Reiter et al. [10] reported that TRPV4 enhanced transcellular  $K^+$  transport and paracellular permeability through  $Ca^{2+}$  signaling in HC11 epithelial monolayers. OGR1 enhanced  $Mg^{2+}$  absorption in intestinal epithelium-like Caco-2 monolayers through protein kinase C (PKC) signaling [11, 12]. On the other hand, an activation of ASIC1a led to a suppression of  $Mg^{2+}$  absorption across Caco-2 monolayers through

✉ Narongrit Thongon  
narongritt@buu.ac.th

Siriporn Chamniansawat  
siripornc@buu.ac.th

<sup>1</sup> Division of Physiology, Department of Biomedical Sciences, Faculty of Allied Health Sciences, Burapha University, 169 Long-Hard Bangsaen Rd, Saensook, Muang, Chonburi 20131, Thailand

<sup>2</sup> Division of Anatomy, Department of Biomedical Sciences, Faculty of Allied Health Sciences, Burapha University, 169 Long-Hard Bangsaen Rd, Saensook, Muang, Chonburi 20131, Thailand

a  $\text{Ca}^{2+}$ -signaling dependent pathway [12]. In addition to acid sensors, the purinergic  $\text{P2Y}_2$  receptor is also involved in mucosal acid sensing and defense of duodenocytes [8]. Activation of  $\text{G}_q$ -associated  $\text{P2Y}_2$  stimulated duodenal mucosal  $\text{HCO}_3^-$  secretion in a  $\text{Ca}^{2+}$  signaling-dependent mechanism [4]. Besides  $\text{HCO}_3^-$  secretion, the  $\text{P2Y}_2$  receptor also regulates  $\text{Na}^+$ ,  $\text{K}^+$ , and  $\text{Cl}^-$  transport in various epithelial tissues [13]. However, the role of  $\text{P2Y}$  on intestinal  $\text{Mg}^{2+}$  absorption is still unknown.

PPI-induced hypomagnesemia (PPIH) has been reported since 2006 [14–19]. Suppression of intestinal  $\text{Mg}^{2+}$  absorption is a major underlying mechanism of PPIH in chronic users and animal models [14, 15, 17, 19–21]. We previously reported that a higher apical  $\text{HCO}_3^-$  secretion contributed to a suppression of intestinal  $\text{Mg}^{2+}$  absorption in PPIH [21]. Apical acidity in the small intestine [22] required for stabilizing mineral solubility [23] and stimulates intestinal  $\text{Mg}^{2+}$  absorption [11, 12, 24]. An increase in luminal pH from ~5 to 7.8 led to a decrease in soluble  $\text{Mg}^{2+}$  from 79.61 to 8.71% [25]; thus, secreted  $\text{HCO}_3^-$  increases luminal pH and subsequently suppresses  $\text{Mg}^{2+}$  absorption. Omeprazole, the most common PPI, significantly enhanced  $\text{HCO}_3^-$  secretion in human duodenum and intestinal epithelium-like Caco-2 monolayers [12, 26]. Antagonists of mucosal  $\text{HCO}_3^-$  secretion markedly increased duodenal  $\text{Mg}^{2+}$  absorption in PPIH rats [21].  $\text{P2Y}_2$  regulated mucosal  $\text{HCO}_3^-$  secretion [4], but the involvement of  $\text{P2Y}_2$  on apical  $\text{HCO}_3^-$  secretion and  $\text{Mg}^{2+}$  absorption in PPI-treated intestinal epithelium is unknown.

Therefore, the present study aimed to investigate the role of purinergic  $\text{P2Y}$  receptors in the regulation of  $\text{Mg}^{2+}$  absorption in normal and omeprazole-treated intestinal-like Caco-2 monolayers. Caco-2 cells express  $\text{P2Y}$  receptors, i.e.,  $\text{P2Y}_2$ ,  $\text{P2Y}_4$ , and  $\text{P2Y}_6$  [27, 28]. They are also equipped with apical  $\text{HCO}_3^-$  secretion transporting machineries, e.g., cystic fibrosis transmembrane conductance regulator (CFTR) and  $\text{Na}^+$ - $\text{HCO}_3^-$  cotransporter-1 (NBCe1), which are modulated by parathyroid hormone (PTH) and  $\text{HCl}$  [12, 29]. In addition, Caco-2 monolayers have been used as a model for studying the regulation of intestinal  $\text{Mg}^{2+}$  absorption [11, 12, 30, 31].

## Methods

### Cell culture

Caco-2 cells (ATCC No. HTB-37, passage 25–40th) were grown in Dulbecco's modified Eagle medium (DMEM) (Sigma, St. Louis, MO, USA) supplemented with 12.5% fetal bovine serum (FBS-Gold) (PAA Laboratories GmbH, Pasching, Austria), 1% L-glutamine (Gibco, Grand Island, NY, USA), 1% non-essential amino acid (Sigma), and 1%

antibiotic–antimycotic solution (Gibco) and maintained in a humidified atmosphere containing 5%  $\text{CO}_2$  at 37 °C. Culture medium was changed 3 times a week. For epithelial electrical parameter measurement and  $\text{Mg}^{2+}$  flux studies, the monolayers were developed by seeding cells ( $5.0 \times 10^5$  cells/ $\text{cm}^2$ ) onto permeable polyester Snapwell™ inserts (12 mm diameter and 0.4  $\mu\text{m}$  pore size filter) (Corning, Corning, NY, USA). After being maintained for 14 days, the Snapwell was inserted into a Ussing chamber (World Precision Instrument, Sarasota, FL, USA). For  $\text{HCO}_3^-$  secretion studies, the cells were plated ( $5.0 \times 10^5$  cells/ $\text{cm}^2$ ) onto permeable polyester Transwell-clear inserts (Corning) and maintained for 14 days. For western blot analysis, cells were plated ( $5.0 \times 10^5$  cells/well) on 6-well plates (Corning) and maintained for 14 days.

In the omeprazole-treated group, Caco-2 monolayers were grown in a culture medium containing omeprazole (Calbiochem, San Diego, CA, USA), from day 7 to day 14 of culture [31], at concentrations of 200 and 400 ng/ml that resembled those found in human plasma [32].

### Bathing solutions

The physiological bathing solution contained (in mM) 118 NaCl, 4.7 KCl, 1.1  $\text{MgCl}_2$ , 1.25  $\text{CaCl}_2$ , 23  $\text{NaHCO}_3$ , 12 D-glucose, 2.5 L-glutamine, and 2 mannitol.

For the apical to basolateral total  $\text{Mg}^{2+}$  transport studies, the apical solution contained (in mM) 40  $\text{MgCl}_2$ , 1.25  $\text{CaCl}_2$ , 4.5 KCl, 12 D-glucose, 2.5 L-glutamine, 115 D-mannitol, and 10 HEPES, whereas the basolateral solution contained (in mM) 1.25  $\text{CaCl}_2$ , 4.5 KCl, 12 D-glucose, 2.5 L-glutamine, 250 D-mannitol, and 10 HEPES.

For apical  $\text{HCO}_3^-$  secretion experiments, the composition of the  $\text{NaHCO}_3$ -free apical solution was as follows (in mM): 1.25  $\text{CaCl}_2$ , 4.5 KCl, 1  $\text{MgCl}_2$ , 12 D-glucose, 2.5 L-glutamine, 230 D-mannitol, and 10 HEPES; and the  $\text{NaHCO}_3$ -containing basolateral solution contained (in mM) 25  $\text{NaHCO}_3$ , 1.25  $\text{CaCl}_2$ , 4.5 KCl, 1  $\text{MgCl}_2$ , 12 D-glucose, 2.5 L-glutamine, 200 D-mannitol, and 10 HEPES.

All solutions were continuously gassed with humidified 5%  $\text{CO}_2$  in 95%  $\text{O}_2$ , maintained at 37 °C, pH 7.4, and had an osmolality of 290–295 mmol  $\text{kg}^{-1}$  water as measured by a freezing-point depression-based Fiske® micro-osmometer (model 210; Fiske® Associates, Norwood, MA, USA). All chemicals were purchased from Sigma.

### Transepithelial electrical resistance

Snapwell™ inserts containing Caco-2 monolayers were rinsed gently, mounted in a Ussing chamber, and bathed on both sides with physiological bathing solution. Transepithelial potential difference (PD) and short-circuit current ( $I_{sc}$ ) were determined by Ag/AgCl electrodes and an epithelial

voltage/current clamp apparatus (model ECV-4000; World Precision Instrument) as previously described [33]. Transepithelial electrical resistance (TEER) was calculated from PD and *I*sc by Ohm's law.

### Mg<sup>2+</sup> transport study

Caco-2 monolayers were rinsed and mounted in a Ussing chamber as described above. After being equilibrated in physiological bathing solution for 15 min, total Mg<sup>2+</sup> transport studies were performed by substituting the physiological bathing solution with apical and basolateral

bathing solutions for Mg<sup>2+</sup> transport. To investigate the Mg<sup>2+</sup> channel-independent Mg<sup>2+</sup> transport, apical sites of Caco-2 monolayers from the same passage and culture plate were pre-incubated for 10 min with Mg<sup>2+</sup>-channel inhibitor Cobalt(III)hexaammine [Co(III)hex, Table 1], which suppressed Mg<sup>2+</sup> influx in Caco-2 epithelium and blocked Mg<sup>2+</sup> channel-dependent Mg<sup>2+</sup> transport. After that the apical and basolateral solutions were substituted with bathing solution for Mg<sup>2+</sup> transport. At 30, 60, and 120 min after solution replacements, 50 µl of solution was collected from the basolateral side, as well as from the apical side. The Mg<sup>2+</sup> concentration and the rate of Mg<sup>2+</sup> flux were determined by the

**Table 1** Agonist, antagonist, or chelator used in the study of Mg<sup>2+</sup> transport and HCO<sub>3</sub><sup>-</sup> secretion across Caco-2 monolayers

Target	Common name	Full name	Concentration used	Manufacturer
<b>Agonist</b>				
Adenylyl cyclase	Forskolin	7β-Acetoxy-8,13-epoxy-1α,6β,9α-trihydroxylabd-14-en-11-one	10 µmol/l	Sigma
P2Y <sub>2</sub> receptor	MRS2768	Uridine-5'-tetraphosphate δ-phenyl ester tetrasodium salt	10 µmol/l	Tocris
P2Y <sub>4</sub> receptor	MRS4062	N <sup>4</sup> -Phenylpropoxycytidine-5'-O-triphosphate tetra(triethylammonium) salt	100 nmol/l	Tocris
P2Y <sub>6</sub> receptor	MRS2693	5-Iodouridine-5'-O-diphosphate trisodium salt	100 nmol/l	Tocris
PKC	Carbachol	(2-Hydroxyethyl)trimethylammonium chloride carbamate	500 µmol/l	Sigma
<b>Antagonist/chelator</b>				
Mg <sup>2+</sup> channel	Co(III)hex	Cobalt(III)hexaammine	1 mmol/l	Sigma
P2Y <sub>2</sub> receptor	Suramin	8,8'-{Carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene) carbonylimino]}bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt	150 µmol/l	Sigma
PLC	U-73122	1-{6-[(17β-3-Methoxyestra-1,3,5(10)-trien-17-yl)amino]hexyl}-1 <i>H</i> -pyrrole-2,5-dione	10 µmol/l	Calbiochem
PKC	Gö 6850	2-[1-(3-Dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide	1 µmol/l	Calbiochem
MEK1/2	U-0126	1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene	10 µmol/l	Calbiochem
PI3K	LY-294002	2-(4-Morpholinyl)-8-phenyl-4 <i>H</i> -1-benzopyran-4-one	75 µmol/l	Calbiochem
PKA	H89	N-[2-( <i>p</i> -Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide	30 µmol/l	Calbiochem
Intracellular Ca <sup>2+</sup>	BAPTA-AM	1,2-Bis(2-aminophenoxy)ethane- <i>N,N,N',N'</i> -tetraacetic acid tetrakis(acetoxymethyl ester)	50 µmol/l	Calbiochem
IP <sub>3</sub> receptor	2-APB	2-Aminoethoxydiphenylborane	100 µmol/l	Calbiochem
Voltage-gated Ca <sup>2+</sup> channel	Nifedipine	1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester	10 µmol/l	Sigma
Membrane-bound CA IX	U-104	4-[[[(4-Fluorophenyl)amino]carbonyl]amino]-benzenesulfonamide	45 nmol/l	Sigma
CFTR	GlyH-101	<i>N</i> -2-Naphthalenyl-2-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene]glycine hydrazide	50 µmol/l	Calbiochem
NBCe1	DIDS	4,4'-Diisothiocyanatostilbene-2,2'-disulfonate	500 µmol/l	Sigma
Ca <sup>2+</sup> -activated K <sup>+</sup> channel	ChTX	Charybdotoxin	100 nmol/l	Tocris
Ca <sup>2+</sup> -activated Cl <sup>-</sup> channel	Benzbromarone	3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran	20 µmol/l	Sigma
CA	Methazolamide	<i>N</i> -(4-Methyl-2-sulfamoyl-Δ <sup>2</sup> -1,3,4-thiadiazolin-5-ylidene)acetamide	1 mmol/l	Sigma

Calbiochem, San Diego, CA; Sigma, St. Louis, MO, USA; Tocris, Tocris Bioscience, Bristol, UK

CA carbonic anhydrase, CFTR cystic fibrosis transmembrane conductance regulator, MEK mitogen-activated protein kinase, NBCe1 Na<sup>+</sup>-HCO<sub>3</sub><sup>-</sup> cotransporter-1, PKA protein kinase A, PKC protein kinase C, PLC phospholipase C, PI3K phosphoinositide 3-kinase, PLC phospholipase C

method of Thongon and Krishnanra [11]. The rate of  $Mg^{2+}$  channel-dependent  $Mg^{2+}$  transport was calculated by subtracting the rate of  $Mg^{2+}$  channel-independent  $Mg^{2+}$  transport from the rate of total  $Mg^{2+}$  transport. However, Co(III) hex might somehow interfered  $Mg^{2+}$  channel-independent paracellular  $Mg^{2+}$  transport, which was not demonstrated in the present study.

In some experiments the monolayers were pre-incubated with agonists or antagonist, as demonstrated in Table 1, for 40 min prior to performing experiments.

### Measurements of $HCO_3^-$ secretion

Apical  $HCO_3^-$  secretion was studied by the modified method of Thongon et al. [12]. The Caco-2 monolayer was gently rinsed 3 times and incubated for 15 min in the physiological bathing solution. Then, apical and basolateral solutions were substituted with bathing solutions for  $HCO_3^-$  secretion. The apical membrane-bound carbonic anhydrase (CA) activity was suppressed by the selective CA IX inhibitor U-104 (Table 1). After 20 min,  $HCO_3^-$  secretion was stimulated by adding MRS2768 or forskolin (Table 1) and incubation proceeded for 5 min. After removal of the MRS2768- or forskolin-containing solutions, the monolayers were gently rinsed 3 times and further incubated for 25 min. Aliquots of apical solution at various time points (Fig. 5) were individually sampled. The concentration of  $HCO_3^-$  was immediately determined as previously described [12].

In some experiments the monolayers were pre-incubated with agonists or antagonist, as demonstrated in Table 1, for 40 min prior to performing experiments.

### Western blot analysis

Western blot analysis was performed as previously described [11]. In brief, protein samples of Caco-2 cells were prepared by using Pierce<sup>®</sup> Ripa Buffer (Thermo Fisher Scientific Inc., Rockford, IL, USA). Protein samples (35  $\mu$ g each) were separated on 12.5% SDS-PAGE gels, and then transferred onto nitrocellulose membranes (Amersham, Buckinghamshire, UK) by electroblotting. Membranes were blocked and probed overnight at 4 °C with 1:1000 rabbit polyclonal antibodies raised against human P2Y<sub>2</sub> receptor and CFTR (Santa Cruz Biotechnology, Santa Cruz, CA). Membranes were also re-probed with actin monoclonal antibodies (Santa Cruz Biotechnology) diluted at 1:5000. After 2 h incubation at 25 °C with goat anti-rabbit IgG-HRP-conjugated secondary antibodies (Santa Cruz Biotechnology) diluted at 1:10,000, blots were visualized by Thermo Scientific SuperSignal<sup>®</sup> West Pico Substrate (Thermo Fisher Scientific Inc.) and captured on CL-XPosure Film (Thermo Fisher Scientific Inc.). Densitometric analysis was performed using ImageJ for Mac Os X.

### Statistical analysis


Results were expressed as mean  $\pm$  SE. Two sets of data were compared using unpaired Student's *t*-test. One-way analysis of variance (ANOVA) with Dunnett's post test was used for comparison of multiple sets of data. The level of significance was  $P < 0.05$ . All data were analyzed by GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA).

## Results

### Omeprazole modulated paracellular $Mg^{2+}$ transport

Previous  $Mg^{2+}$  transport kinetic analysis demonstrated that omeprazole selectively impeded non-saturable passive  $Mg^{2+}$  transport but not saturable active  $Mg^{2+}$  transport across Caco-2 monolayers [31]. By using competitive  $Mg^{2+}$ -channel inhibitor Co(III)hex (Fig. 1), we observed total (white bars),  $Mg^{2+}$  channel-independent (gray bars), and  $Mg^{2+}$  channel-dependent  $Mg^{2+}$  transport (black bars). The results showed that 200 and 400 ng/ml omeprazole significantly suppressed total (Fig. 1d) and  $Mg^{2+}$  channel-independent  $Mg^{2+}$  transport (Fig. 1e) compared to the control group. Furthermore, we had studied the effect of omeprazole on  $Mg^{2+}$  channel-independent  $Mg^{2+}$  transport. Previously, it was reported that protein kinase C activator carbachol (CCh) could increase paracellular permeability and decrease TEER in Caco-2 monolayers [34, 35]. In control (Fig. 1a), 200-ng/ml omeprazole-treated group (Fig. 1b), and 400-ng/ml omeprazole-treated group (Fig. 1c), CCh significantly increased total and  $Mg^{2+}$  channel-independent  $Mg^{2+}$  transport compared to the corresponding vehicle-treated group. The rates of  $Mg^{2+}$  channel-dependent  $Mg^{2+}$  transport of all experiments were not changed (Fig. 1a–c, f).

We also studied TEER to confirm the permeability of Caco-2 monolayers. As demonstrated in Fig. 2c, Co(III)hex, which impeded  $Mg^{2+}$  channel-dependent  $Mg^{2+}$  transport, had no effect on TEER of control and omeprazole-treated monolayers when compared to its corresponding vehicle-treated monolayers. On the other hand CCh, which increased  $Mg^{2+}$  channel-independent  $Mg^{2+}$  transport, significantly decreased TEER of control and omeprazole-treated (Fig. 2c) Caco-2 monolayers. We further observed the involvement of  $Ca^{2+}$ -activated  $K^+$  and  $Ca^{2+}$ -activated  $Cl^-$  channels on CCh-suppressed TEER by using charybdotoxin (ChTX) and benzbrumarone. ChTX and benzbrumarone had no effect on CCh-suppressed TEER of control and omeprazole-treated Caco-2 monolayers. However, CCh might somehow modulate some ion channels or transports, which could affect TEER of Caco-2 monolayers. TEER of 400-ng/ml omeprazole-treated monolayers ( $458.56 \pm 14.97 \Omega \text{ cm}^2$ ) was significantly higher than that of vehicle-treated control monolayers



**Fig. 1** Effect of omeprazole on  $Mg^{2+}$  transport across Caco-2 monolayers. The rate of  $Mg^{2+}$  transport across control (a), 200-ng/ml omeprazole-treated (b), and 400-ng/ml omeprazole-treated Caco-2 monolayers (c). White bar; total  $Mg^{2+}$  transport, gray bar;  $Mg^{2+}$  channel-independent  $Mg^{2+}$  transport, black bar;  $Mg^{2+}$  channel-dependent  $Mg^{2+}$  transport. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$


compared with its corresponding CCh-untreated group. ( $n = 6$ ). The rate of total (d),  $Mg^{2+}$ -channel independent (e), and  $Mg^{2+}$ -channel dependent (f)  $Mg^{2+}$  transport of control and omeprazole-treated Caco-2 monolayers. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$  compared with its corresponding control group ( $n = 6$ )

( $362.31 \pm 17.69 \Omega \text{ cm}^2$ ,  $P = 0.0003$ ) (Fig. 2c). This series of experiments suggested that alteration of total  $Mg^{2+}$  transport across Caco-2 monolayers was the result of the modulation of  $Mg^{2+}$  channel-independent  $Mg^{2+}$  transport. These results also agreed with a previous study [31] that omeprazole exclusively suppressed nonsaturable passive  $Mg^{2+}$  transport in intestinal epithelium-like Caco-2 monolayers. In addition, TEER could determine the change of  $Mg^{2+}$  channel-independent  $Mg^{2+}$  transport, but not  $Mg^{2+}$  channel-dependent  $Mg^{2+}$  transport. Thus,  $Mg^{2+}$  channel-dependent  $Mg^{2+}$  transport was ignored in the rest of the experiments.

### P2Y<sub>2</sub> receptor modulated $Mg^{2+}$ transport

To observe the roles of P2Y<sub>2</sub>, P2Y<sub>4</sub>, and P2Y<sub>6</sub> activities on  $Mg^{2+}$  transport across Caco-2 monolayers we incubated the monolayers with selective agonists of P2Y<sub>2</sub>, P2Y<sub>4</sub>, or P2Y<sub>6</sub> receptors (Table 1). In control monolayers (Fig. 3a) the rate of  $Mg^{2+}$  transport (in  $\text{nmol/h/cm}^2$ ) of the P2Y<sub>2</sub> agonist-treated group ( $81.14 \pm 3.45$ ), but not P2Y<sub>4</sub> or P2Y<sub>6</sub> agonist-treated groups, was significantly lower than that of the vehicle-treated group ( $138.89 \pm 4.85$ ). As demonstrated

in Fig. 3b, the rate of  $Mg^{2+}$  transport (in  $\text{nmol/h/cm}^2$ ) of the P2Y<sub>2</sub> agonist-treated group ( $41.94 \pm 5.91$ ) was significantly lower than that of vehicle-treated group ( $106.74 \pm 5.12$ ) in the 200-ng/ml omeprazole-treated condition. In 400-ng/ml omeprazole-treated monolayers (Fig. 3c),  $Mg^{2+}$  transport (in  $\text{nmol/h/cm}^2$ ) of the P2Y<sub>2</sub> agonist-treated group ( $35.28 \pm 2.72$ ) was also significantly suppressed compared to the vehicle-treated group ( $95.24 \pm 4.96$ ). When compared to the corresponding vehicle-treated group, P2Y<sub>2</sub> agonist suppressed the rate of  $Mg^{2+}$  transport by about 41.58, 60.71, and 62.96% of control, in the 200-ng/ml omeprazole-treated, and 400-ng/ml omeprazole-treated monolayers, respectively. In addition, TEER of MRS2768 treated monolayers was significantly higher than that of the corresponding vehicle-treated control (Fig. 2a) or omeprazole-treated monolayers (Fig. 2b). We further performed a western blotting study to confirm the enhancing effect of omeprazole on P2Y<sub>2</sub> receptor activation in suppressing intestinal  $Mg^{2+}$  absorption. As demonstrated in Fig. 3d, 200 and 400 ng/ml omeprazole significantly enhanced P2Y<sub>2</sub> expression when compared to the control cells.




**Fig. 2** Transepithelial electrical resistance (TEER). TEER of control and 400-ng/ml omeprazole-treated Caco-2 monolayers in various experiments. \* $P < 0.05$ , \*\* $P < 0.01$  compared with its corresponding vehicle-treated group ( $n = 6$ ). *Benzb* benzbromarone

### Signaling pathway of P2Y<sub>2</sub> receptor activation suppressed Mg<sup>2+</sup> transport

This series of experiments aimed to observe the underlying mechanism by which P2Y<sub>2</sub> receptor activation mediated

the suppression of intestinal Mg<sup>2+</sup> absorption. In control (Fig. 4a) and omeprazole-treated Caco-2 monolayers (Fig. 4b), MRS2768 significantly suppressed the rate of total Mg<sup>2+</sup> transport. P2Y<sub>2</sub> receptor antagonist, PLC antagonist, IP<sub>3</sub> receptor antagonist, and intracellular Ca<sup>2+</sup>

**Fig. 3** The effect of P2Y receptor agonists on  $Mg^{2+}$  transport across Caco-2 monolayers. The rate of  $Mg^{2+}$  transport across control (a), 200-ng/ml omeprazole-treated (b), and 400-ng/ml omeprazole-treated Caco-2 monolayers (c) with agonist of P2Y<sub>2</sub> receptor MRS2768, P2Y<sub>4</sub> receptor MRS4062, and P2Y<sub>6</sub> receptor MRS2693 pre-incubations. Representative immunoblotting and densitometric analysis of P2Y<sub>2</sub> expression in control and omeprazole-treated Caco-2 cells (d). \*\*\* $P < 0.001$  compared with its vehicle-treated group ( $n = 6$ )




chelator markedly normalized the effect of MRS2768 on  $Mg^{2+}$  transport. However, the antagonist of PKC, MEK1/2, PI3K, PKA, or voltage-gated  $Ca^{2+}$  channel had no effect on MRS2768-suppressed  $Mg^{2+}$  transport in either control or omeprazole-treated Caco-2 monolayers (Fig. 4a–b). In the TEER study, P2Y<sub>2</sub> receptor antagonist, PLC antagonist, IP<sub>3</sub> receptor antagonist, and intracellular  $Ca^{2+}$  chelator also normalized the effect of MRS2768-increased TEER of control (Fig. 2a) and omeprazole-treated (Fig. 2b) monolayers. These results suggested that P2Y<sub>2</sub> receptor activation mediated the suppression of intestinal  $Mg^{2+}$  absorption through PLC, IP<sub>3</sub> receptor, and intracellular  $Ca^{2+}$  signaling pathway.

### Contribution of $HCO_3^-$ secretion on P2Y<sub>2</sub> receptor activation suppressed $Mg^{2+}$ transport

Previously, we reported the contribution of mucosal  $HCO_3^-$  secretion on omeprazole-suppressed duodenal  $Mg^{2+}$  absorption in PPIH rats [21]. Then, we further studied the contribution of  $HCO_3^-$  secretion on P2Y<sub>2</sub> receptor activation-suppressed  $Mg^{2+}$  transport in Caco-2


monolayers. As demonstrated in Fig. 5a and b, P2Y<sub>2</sub> agonist significantly suppressed  $Mg^{2+}$  transport in control and omeprazole-treated monolayers. The antagonist of NBCe1, CFTR, and CA could relieve the inhibitory effect of P2Y<sub>2</sub> activation on  $Mg^{2+}$  transport across control and omeprazole-treated monolayers (Fig. 5a–b). By using  $HCO_3^-$ -free bathing solution in both apical and basolateral sites, the P2Y<sub>2</sub> agonist had no effect on  $Mg^{2+}$  transport in normal Caco-2 monolayers (Fig. 5a). In omeprazole-treated monolayers (Fig. 5b), the  $HCO_3^-$ -free condition significantly increased  $Mg^{2+}$  transport when compared to its corresponding vehicle-treated group. Under the  $HCO_3^-$ -free condition, the P2Y<sub>2</sub> agonist also had no effect on  $Mg^{2+}$  transport in omeprazole-treated Caco-2 monolayers (Fig. 5b). Moreover, the antagonist of CFTR, CA, and NBCe1 also normalized the effect of P2Y<sub>2</sub> activation-increased TEER of control (Fig. 2a) and omeprazole-treated (Fig. 2b) Caco-2 monolayers. Therefore, apical  $HCO_3^-$  secretion was involved in P2Y<sub>2</sub> receptor activation-suppressed  $Mg^{2+}$  transport.



**Fig. 4** The signaling pathway of P2Y receptor activation suppressed  $Mg^{2+}$  transport across Caco-2 monolayers. The rate of  $Mg^{2+}$  transport across control (a) and 400-ng/ml omeprazole-treated Caco-2 monolayers (b) with agonist or antagonist pre-incubations. \*\*\* $P < 0.001$  compared with its vehicle-treated group ( $n = 6$ )

### P2Y<sub>2</sub> receptor activation stimulated $HCO_3^-$ secretion

Previously, it was reported that P2Y<sub>2</sub> stimulated mucosal  $HCO_3^-$  secretion in rat duodenum [4]. The present study observed the effect of P2Y<sub>2</sub> receptor activation on apical  $HCO_3^-$  secretion in Caco-2 monolayers. Since forskolin stimulated duodenum  $HCO_3^-$  secretion in mice [36] and apical  $HCO_3^-$  secretion in Caco-2 monolayers [29], we used forskolin as positive control for the stimulation of apical  $HCO_3^-$  secretion. Our results showed that P2Y<sub>2</sub> agonist MRS2768 and forskolin significantly increased the rate of apical  $HCO_3^-$  secretion by control (Fig. 6a, b), 200-ng/ml omeprazole-treated (Fig. 6c, d), and 400-ng/ml omeprazole-treated (Fig. 6e, f) monolayers. Under the  $HCO_3^-$ -free condition, the rate of basal, forskolin-stimulated, and MRS2768-stimulated  $HCO_3^-$  secretions were suppressed in control and omeprazole-treated Caco-2 monolayers (Fig. 6b, d, f). In the pre-stimulating condition





**Fig. 5** Contribution of  $HCO_3^-$  secretion on P2Y receptor activation suppressed  $Mg^{2+}$  transport across Caco-2 monolayers. The rate of  $Mg^{2+}$  transport across control (a), and 400-ng/ml omeprazole-treated Caco-2 monolayers (b) with agonist or antagonist pre-incubations. \* $P < 0.05$ , \*\*\* $P < 0.001$  compared with its vehicle-treated group ( $n = 6$ )

(Fig. 6g), the basal  $HCO_3^-$  secretions (in  $\mu\text{mol/h/cm}^2$ ) of 200-ng/ml omeprazole-treated ( $4.45 \pm 0.46$ ) and 400-ng/ml omeprazole-treated ( $5.19 \pm 0.49$ ) monolayers were significantly higher than that of the control monolayers ( $2.49 \pm 0.41$ ). The rate of peak  $HCO_3^-$  secretions (in  $\mu\text{mol/h/cm}^2$ ) in forskolin-stimulated and MRS2768-stimulated conditions (Fig. 6h) of 200-ng/ml omeprazole-treated ( $12.48 \pm 0.46$  and  $13.01 \pm 0.57$ , respectively) and 400-ng/ml omeprazole-treated ( $14.12 \pm 0.44$  and  $14.59 \pm 0.48$ , respectively) monolayers were significantly higher than those of the control monolayers ( $9.16 \pm 0.68$  and  $8.66 \pm 0.57$ , respectively). We further observed the expression of CFTR protein in omeprazole-treated monolayers. As demonstrated in Fig. 7a, omeprazole had no effect on CFTR protein expression in Caco-2 monolayers.



**Fig. 6** P2Y<sub>2</sub> receptor agonist stimulated HCO<sub>3</sub><sup>-</sup> secretion. Time course and rate of apical HCO<sub>3</sub><sup>-</sup> secretion by control (a, b), 200-ng/ml omeprazole-treated (c, d), and 400-ng/ml omeprazole-treated Caco-2 monolayers (e, f) that were induced by forskolin or MRS2768. Basal (at 20 min; g) and peak forskolin- or MRS2768-stimulated HCO<sub>3</sub><sup>-</sup> secretion (at 33 min; h) by control or omeprazole-exposed Caco-2 monolayers. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001 compared with the corresponding control group. †*P* < 0.05, ††*P* < 0.01, †††*P* < 0.001 compared with the pre-treated control group (*n* = 6)





**Fig. 7** The signaling pathway of P2Y<sub>2</sub> receptor agonist stimulated HCO<sub>3</sub><sup>-</sup> secretion. Representative immunoblotting and densitometric analysis of CFTR expression in control and omeprazole-treated Caco-2 cells (a). The rate of peak MRS2768-stimulated HCO<sub>3</sub><sup>-</sup> secretion by control (b), and 400-ng/ml omeprazole-treated Caco-2

monolayers (c) that were induced by agonist or antagonist. The pH of apical culture media of Caco-2 monolayers at 24 h after culture media change (d). \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001 compared with the corresponding vehicle group (*n* = 6)

### Signaling pathway of P2Y<sub>2</sub> receptor activation stimulated HCO<sub>3</sub><sup>-</sup> secretion

Previously, it was found that P2Y<sub>2</sub> activation enhanced mucosal HCO<sub>3</sub><sup>-</sup> secretion through PLC, IP<sub>3</sub> receptor, and intracellular Ca<sup>2+</sup> signaling pathway [4]. This series of experiments, therefore, showed the underlying signaling transduction pathway of P2Y<sub>2</sub> receptor activation that mediated the stimulation of apical HCO<sub>3</sub><sup>-</sup> secretion in Caco-2 monolayers. In control (Fig. 7b) and omeprazole-treated monolayers (Fig. 7c), the rate of peak MRS2768-stimulated HCO<sub>3</sub><sup>-</sup> secretion was significantly suppressed in the monolayers treated with the antagonist of P2Y<sub>2</sub> receptor, PLC, PI3K receptor, CFTR, NBCe1, and CA, as well as intracellular Ca<sup>2+</sup> chelator. These results showed that P2Y<sub>2</sub> receptor activation mediated the stimulation of HCO<sub>3</sub><sup>-</sup> secretion through PLC, IP<sub>3</sub> receptor, and intracellular Ca<sup>2+</sup> signaling pathway. We further observed the pH of apical culture media of Caco-2 monolayers at 24 h after culture media change.

MRS2768 and 400 ng/ml omeprazole significantly increased apical pH compared to vehicle treated group (Fig. 7d). CFTR and NBCe1 antagonists significantly abolished MRS2768 and omeprazole effects on apical pH.

### Discussion

Intestinal Mg<sup>2+</sup> absorption can be processed through saturable transcellular and non-saturable paracellular mechanisms. Transcellular Mg<sup>2+</sup> transport is an active process that requires the activity of transient receptor potential melastatin 6 (TRPM6), TRPM7, and basolateral Na<sup>+</sup>/Mg<sup>2+</sup> exchanger [1, 37–39] or other transport pathways. Paracellular Mg<sup>2+</sup> transport is a passive mechanism modulated by the tight junction associated Claudin (Cldn) [11, 40]. However, the regulatory mechanism of intestinal Mg<sup>2+</sup> absorption is largely unknown.

Our previous study demonstrated that intestinal-associated proton sensors ASIC1a and OGR1 could modulate intestinal-like  $Mg^{2+}$  transport across Caco-2 monolayers [12]. OGR1 activation increased  $Mg^{2+}$  transport across Caco-2 monolayers while ASIC1a activation decreased it. In the present study we focused on the role of the purinergic  $P2Y_1$  receptor family, which was regulating trans-epithelial  $Na^+$ ,  $K^+$ , and  $Cl^-$  transport [13], on  $Mg^{2+}$  transport across Caco-2 monolayers. The  $G_q$ -coupled  $P2Y_1$  receptor family is composed of  $P2Y_1$ ,  $P2Y_2$ ,  $P2Y_4$ ,  $P2Y_6$  and  $P2Y_{11}$  receptors. However, Caco-2 monolayers expressed  $P2Y_2$ ,  $P2Y_4$ , and  $P2Y_6$  [27], which are exclusively localized in the apical membrane [28]. Our results suggested that only  $P2Y_2$  was involved in the modulation of  $Mg^{2+}$  transport across Caco-2 monolayers. Generally,  $P2Y_2$  receptors regulate epithelial ion transport through  $G_q$ -dependent pathways which activate PLC and stimulate intracellular  $Ca^{2+}$  mobilization [4, 13]. In agreement with our results,  $P2Y_2$  receptor activation suppressed  $Mg^{2+}$  transport through PLC,  $IP_3$  receptor, and the intracellular  $Ca^{2+}$  signaling pathway. Li et al. [41] reported the inhibitory role of  $P2Y_2$  receptor on *Cldn-1* expression. Purinergic  $P2Y$  receptor agonist adenosine triphosphate (ATP) rapidly suppressed epithelial paracellular permeability and increased epithelial TEER [42]. In addition, purinergic  $P2$  receptor agonist also suppressed the activity of TRPM6 and TRPM7 [43, 44]. However, the role of  $P2Y_2$  on *Cldn*, TRPM6, and TRPM7 expressions and functions required further studies.

Duodenal mucosal bicarbonate secretion (DMBS) is the critical process of duodenal defense against intermittent duodenal epithelial exposure to a luminal acidic environment ( $pH < 2$ ). Luminal  $H^+$  is the potent activator of DMBS by stimulating a duodenal associated acid sensor, e.g., ASIC1a [5]. In addition, luminal uridine triphosphate, a  $P2Y_2$  agonist, also stimulates DMBS [4]. Previously, apical  $HCO_3^-$  secretion had been observed in Caco-2 monolayers [12, 29]. Laohapitakworn et al. [29] reported that PTH rapidly stimulated CFTR-, CA-, and NBCe1-mediated apical  $HCO_3^-$  secretion in Caco-2 monolayers. Our group demonstrated that activation of ASIC1a stimulated an apical  $HCO_3^-$  secretion CFTR-dependent mechanism [12]. In the present study we reported the activation of  $P2Y_2$  receptor stimulating CFTR-, CA-, and NBCe1-mediated apical  $HCO_3^-$  secretion in Caco-2 monolayers. Our results agreed with the finding of a previous report [4] that showed  $P2Y_2$  receptor activation mediated the stimulation of intestinal  $HCO_3^-$  secretion through PLC,  $IP_3$  receptor, and the intracellular  $Ca^{2+}$  signaling pathway.

The underlying mechanism of PPI-suppressed intestinal  $Mg^{2+}$  uptake is still unclear. A previous mathematically simulated study suggested that only a 1% reduction of intestinal  $Mg^{2+}$  absorption could induce 80%  $Mg^{2+}$  depletion within 1 year of PPIs used [45]. Previous studies proposed that

PPIs mainly affected colonic  $Mg^{2+}$  absorption in PPIH mice [2, 20]. Our group reported that PPIs impeded duodenal  $Mg^{2+}$  absorption in PPIH rats [21]. We hypothesized that a higher luminal  $HCO_3^-$  secretion could lead to a suppression of small intestinal  $Mg^{2+}$  absorption in PPIH [12, 21]. Omeprazole markedly enhanced  $HCO_3^-$  secretion in human duodenum and intestinal epithelium-like Caco-2 monolayers [12, 26]. Secreted  $HCO_3^-$  increased luminal pH and probably decreased  $Mg^{2+}$  solubility, since luminal soluble  $Mg^{2+}$  decreased from 79.61 to 8.71% when luminal pH increased from ~5 to 7.8 [25]. Therefore, antagonists of CFTR and NBCe1 significantly increased duodenal  $Mg^{2+}$  absorption in PPIH rats [21]. These findings agreed with the present study that omeprazole induced basal and peak-stimulated  $HCO_3^-$  secretion. Interestingly, in the  $HCO_3^-$ -free condition the rate of  $Mg^{2+}$  transport markedly increased in omeprazole-treated Caco-2 monolayers, suggesting the inhibitory role of secreted  $HCO_3^-$  on intestinal  $Mg^{2+}$  absorption. However, luminal  $Mg^{2+}$  solubility and precipitation in the PPI-treated animal model requires further study.

The present study showed higher  $P2Y_2$  expression in omeprazole-treated Caco-2 monolayers. Thus,  $P2Y_2$ -activated  $HCO_3^-$  secretion was also significantly higher in omeprazole-treated monolayers. These results explained the higher degree of suppression of  $Mg^{2+}$  absorption in  $P2Y_2$ -activated 200-ng/ml omeprazole-treated (60.71%) and 400-ng/ml omeprazole-treated monolayers (62.96%) in comparison to control monolayers (41.58%). Moreover,  $P2Y_2$  activation enhanced  $HCO_3^-$  secretion and suppressed  $Mg^{2+}$  absorption were also mediated by PLC,  $IP_3$  receptor, intracellular  $Ca^{2+}$  mobilization, CFTR, CA, and NBCe1. In addition to higher  $HCO_3^-$  secretion, another possible mechanism of omeprazole-suppressed  $Mg^{2+}$  absorption is phosphatidylinositol 4,5-bisphosphate ( $PIP_2$ )-mediated TRPM6 function. Since TRPM6 function required an interaction with membrane-associated  $PIP_2$ , hydrolysis of  $PIP_2$  through activation of the  $G_q$ -protein coupled PLC-dependent pathway fully inactivated TRPM6 channels [46]. The higher  $G_q$ -associated  $P2Y_2$  expression and function might have induced  $PIP_2$  degradation which then inactivated TRPM6 channels in omeprazole-treated Caco-2 monolayers. However, our results suggested that  $Mg^{2+}$  channel-dependent  $Mg^{2+}$  absorption could not be involved in omeprazole-suppressed  $Mg^{2+}$  transport across Caco-2 monolayers.

Our results in the present study agreed with the previous study [8] that omeprazole suppressed  $Mg^{2+}$  channel-independent, but not  $Mg^{2+}$  channel-dependent,  $Mg^{2+}$  transport across Caco-2 monolayers. There are two possible answers to explain why omeprazole had no effect on  $Mg^{2+}$  channel-dependent  $Mg^{2+}$  transport across Caco-2 monolayers. Since omeprazole has no effect on TRPM6 expression in Caco-2 cells [21],  $Mg^{2+}$  channel-dependent  $Mg^{2+}$  transport was maintained in the same fraction. Regarding our recent results, from 100% of total

Mg<sup>2+</sup> transport, the percentages of Mg<sup>2+</sup> channel-dependent Mg<sup>2+</sup> transport were 18.55, 19.02, and 18.58% in control, 200-ng/ml omeprazole-treated, and 400-ng/ml omeprazole-treated monolayers. On the other hand, our recent method may not be sensitive enough to detect a very small change of Mg<sup>2+</sup> channel-dependent Mg<sup>2+</sup> transport of omeprazole-treated Caco-2 monolayers.

In conclusion, the present study reported the role of P2Y<sub>2</sub> function on the modulation of intestinal Mg<sup>2+</sup> absorption. P2Y<sub>2</sub> agonist enhanced HCO<sub>3</sub><sup>-</sup> secretion and suppressed Mg<sup>2+</sup> transport through the activation of PLC, IP<sub>3</sub> receptor, intracellular Ca<sup>2+</sup> mobilization, CFTR, CA, and NBCe1. Inhibition of HCO<sub>3</sub><sup>-</sup> secretion could restore Mg<sup>2+</sup> transport in P2Y<sub>2</sub> agonist-treated monolayers. The higher P2Y<sub>2</sub> expression was found in omeprazole-treated Caco-2 monolayers. Therefore, the higher degree of HCO<sub>3</sub><sup>-</sup> secretion and Mg<sup>2+</sup> transport suppression was demonstrated in P2Y<sub>2</sub>-activated omeprazole-treated Caco-2 monolayers. Our results propose an inhibitory role of P2Y<sub>2</sub> on intestinal Mg<sup>2+</sup> absorption.

**Acknowledgements** This study was supported by research grants from Burapha University through the National Research Council of Thailand (138/2560), and the Faculty of Allied Health Sciences, Burapha University (AHS06/2560) to N. Thongon. We express our gratitude to Dr. Prasert Sobhon of the Faculty of Allied Health Sciences, Burapha University for his helpful suggestions and proofreading. We also thank Dr. Petcharat Trongtorsak of Allied Health Sciences, Burapha University for a very kind gift of forskolin, CCh, and nifedipine. We also thank Ms. Pattamaporn Ketkeaw and Mr. Chanin Nuekchob of the Faculty of Allied Health Sciences, Burapha University and Mr. Phongthon Kanjanasirirat of the Excellent Center for Drug Discovery (ECDD), Faculty of Science, Mahidol University for their excellent technical assistance.

**Author contributions** TN designed and performed the experiments, analyzed and interpreted the results, and wrote and edited the manuscript. CS performed the experiments, analyzed the results, and wrote and edited the manuscript.

**Funding** This study was funded by Burapha University through the National Research Council of Thailand (138/2560), and the Faculty of Allied Health Sciences, Burapha University (AHS06/2560) to N. Thongon.

## Compliance with ethical standards

**Conflict of interest** All authors declare that they have no competing interests.

**Ethical approval** This article does not contain any studies with human participants or animals performed by any of the authors.

**Informed consent** Not applicable.

## References

- de Baaij JHF, Hoenderop JG, Bindels RJM (2015) Magnesium in man: implications for health and disease. *Physiol Rev* 95(1):1–46
- Lameris ALL, Hess MW, van Kruijsbergen I, Hoenderop JGJ, Bindels RJM (2013) Omeprazole enhances the colonic expression of the Mg<sup>2+</sup> transporter TRPM6. *Pflugers Arch Eur J Physiol* 465(11):1613–1620
- Quamme GA (2008) Recent developments in intestinal magnesium absorption. *Curr Opin Gastroenterol* 24(2):230–235
- Dong X, Smoll EJ, Ko KH, Lee J, Chow JY, Kim HD, Insel PA, Dong H (2009) P2Y receptors mediate Ca<sup>2+</sup> signaling in duodenocytes and contribute to duodenal mucosal bicarbonate secretion. *Am J Physiol Gastrointest Liver Physiol* 296(2):G424–G432
- Dong X, Ko KH, Chow J, Tuo B, Barrett KE, Dong H (2011) Expression of acid-sensing ion channels in intestinal epithelial cells and their role in the regulation of duodenal mucosal bicarbonate secretion. *Acta Physiol* 201:97–107
- Holzer P (2007) Taste receptors in the gastrointestinal tract. V. Acid-sensing in the gastrointestinal tract. *Am J Physiol Gastrointest Liver Physiol* 292:G699–G705
- Holzer P (2009) Acid-sensitive ion channels and receptors. *Handb Exp Pharmacol* 194:283–332
- Kaunitz JD, Akiba Y (2011) Purinergic regulation of duodenal surface pH and ATP concentration: implications for mucosal defence, lipid uptake and cystic fibrosis. *Acta Physiol* 201(1):109–116
- Xu Y, Casey G (1996) Identification of human OGR1, a novel G protein-coupled receptor that maps to chromosome 14. *Genomics* 35:397–402
- Reiter B, Kraft R, Günzel D, Zeissig S, Schulzke J-D, Fromm M, Harteneck C (2006) TRPV4-mediated regulation of epithelial permeability. *FASEB J* 20:1802–1812
- Thongon N, Krishnamra N (2012) Apical acidity decreases inhibitory effect of omeprazole on Mg<sup>2+</sup> absorption and claudin-7 and -12 expression in Caco-2 monolayers. *Exp Mol Med* 44(11):684–693
- Thongon N, Ketkeaw P, Nuekchob C (2014) The roles of acid-sensing ion channel 1a and ovarian cancer G protein-coupled receptor 1 on passive Mg<sup>2+</sup> transport across intestinal epithelium-like Caco-2 monolayers. *J Physiol Sci* 64(2):129–139
- Leipzig J (2003) Control of epithelial transport via luminal P2 receptors. *Am J Physiol Ren Physiol* 284(3):F419–F432
- Cundy T, Dissanayake A (2008) Severe hypomagnesemia in long-term users of proton-pump inhibitors. *Clin Endocrinol* 69:338–341
- Cundy T, Mackay J (2011) Proton pump inhibitors and severe hypomagnesemia. *Curr Opin Gastroenterol* 27(2):180–185
- Danziger J, William JH, Scott DJ, Lee J, Lehman LW, Mark RG, Howell MD, Celi LA, Mukamal KJ (2013) Proton-pump inhibitor use is associated with low serum magnesium concentrations. *Kidney Int* 83(4):692–699
- Epstein M, McGrath S, Law F (2006) Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. *N Engl J Med* 355:1834–1836
- Luk CP, Parsons R, Lee YP, Hughes JD (2013) Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? *Ann Pharmacother* 47(6):773–780
- Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW (2008) Omeprazole and refractory hypomagnesemia. *BMJ* 337:a425
- Hess MW, de Baaij JHF, Gommers LMM, Hoenderop JGJ, Bindels RJM (2015) Dietary inulin fibers prevent proton-pump inhibitor (PPI)-induced hypocalcemia in mice. *PLoS One* 10(9):e0138881
- Thongon N, Penguy J, Kulwong S, Khongmueang K, Thongma M (2016) Omeprazole suppressed plasma magnesium level and duodenal magnesium absorption in male Sprague-Dawley rats. *Pflugers Arch Eur J Physiol* 468(11–12):1809–1821
- Nugent SG, Kumar D, Rampton DS, Evans DF (2001) Intestinal luminal pH in inflammatory bowel disease: possible determinants

- and implications for therapy with aminosalicylates and other drugs. *Gut* 48:571–577
23. Evenepoel P (2001) Alteration in digestion and absorption of nutrients during profound acid suppression. *Best Pract Res Clin Gastroenterol* 15:539–551
  24. Heijnen AM, Brink EJ, Lemmens AG, Beynen AC (1993) Ileal pH and apparent absorption of magnesium in rats fed on diets containing either lactose or lactulose. *Br J Nutr* 70:747–756
  25. Ben-Ghedalia D, Tagari H, Zamwel S, Bondi A (1975) Solubility and net exchange of calcium, magnesium and phosphorus in digesta flowing along the gut of the sheep. *Br J Nutr* 33(1):87–94
  26. Mertz-Nielsen A, Hillingsø J, Bukhave K, Rask-Madsen J (1996) Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans. *Gut* 38:6–10
  27. McAlroy HL, Ahmed S, Day SM, Baines DL, Wong HY, Yip CY, Ko WH, Wilson SM, Collett A (2000) Multiple P2Y receptor subtypes in the apical membranes of polarized epithelial cells. *Br J Pharmacol* 131(8):1651–1658
  28. Wolff SC, Qi AD, Harden TK, Nicholas RA (2005) Polarized expression of human P2Y receptors in epithelial cells from kidney, lung, and colon. *Am J Physiol Cell Physiol* 288(3):C624–C632
  29. Laohapitakworn S, Thongbunchoo J, Nakkrasae LI, Krishnamra N, Charoenphandhu N (2011) Parathyroid hormone (PTH) rapidly enhances CFTR-mediated  $\text{HCO}_3^-$  secretion in intestinal epithelium-like Caco-2 monolayer: a novel ion regulatory action of PTH. *Am J Physiol Cell Physiol* 301(1):C137–C149
  30. Ekmekcioglu C, Ekmekcioglu A, Marktl W (2000) Magnesium transport from aqueous solutions across Caco-2 cells—an experimental model for intestinal bioavailability studies. *Physiological considerations and recommendations. Magnes Res* 13:93–102
  31. Thongon N, Krishnamra N (2011) Omeprazole decreases magnesium transport across Caco-2 monolayers. *World J Gastroenterol* 17(12):1574–1583
  32. Macek J, Klíma J, Ptáček P (2007) Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. *J Chromatogr B Anal Technol Biomed Life Sci* 852:282–287
  33. Thongon N, Nakkrasae LI, Thongbunchoo J, Krishnamra N, Charoenphandhu N (2008) Prolactin stimulates transepithelial calcium transport and modulates paracellular permselectivity in Caco-2 monolayer: mediation by PKC and ROCK pathways. *Am J Physiol Cell Physiol* 294:C1158–C1168
  34. Blais A, Aymard P, Lacour B (1997) Paracellular calcium transport across Caco-2 and HT29 cell monolayers. *Pflugers Arch* 434(3):300–305
  35. Stenson WF, Easom RA, Riehl TE, Turk J (1993) Regulation of paracellular permeability in Caco-2 cell monolayers by protein kinase C. *Am J Physiol* 265(5 Pt 1):G955–G962
  36. Singh AK, Liu Y, Riederer B, Engelhardt R, Thakur BK, Soleimani M, Seidler U (2013) Molecular transport machinery involved in orchestrating luminal acid-induced duodenal bicarbonate secretion in vivo. *J Physiol* 591(21):5377–5391
  37. Ryazanova LV, Rondon LJ, Zierler S, Hu Z, Galli J, Yamaguchi TP, Mazur A, Fleig A, Ryazanov AG (2010) TRPM7 is essential for  $\text{Mg}^{2+}$  homeostasis in mammals. *Nat Commun* 1:109
  38. Li M, Jiang J, Yue L (2006) Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. *J Gen Physiol* 127(5):525–537
  39. Yamazaki D, Funato Y, Miura J, Sato S, Toyosawa S, Furutani K, Kurachi Y, Omori Y, Furukawa T, Tsuda T, Kuwabata S, Mizukami S, Kikuchi K, Miki H (2013) Basolateral  $\text{Mg}^{2+}$  extrusion via CNNM4 mediates transcellular  $\text{Mg}^{2+}$  transport across epithelia: a mouse model. *PLoS Genet* 9(12):e1003983
  40. Hou J, Renigunta A, Konrad M, Gomes AS, Schneeberger EE, Pual DL, Waldegger S, Goodenough DA (2008) Clauin-16 and claudin-19 interact and form a cation-selective tight junction complex. *J Clin Invest* 118:619–628
  41. Li WH, Qiu Y, Zhang HQ, Liu Y, You JF, Tian XX, Fang WG (2013) P2Y<sub>2</sub> receptor promotes cell invasion and metastasis in prostate cancer cells. *Br J Cancer* 109(6):1666–1675
  42. Gorodeski GI, Hopfer U (1995) Regulation of the paracellular permeability of cultured human cervical epithelium by a nucleotide receptor. *J Soc Gynecol Investig* 2(5):716–720
  43. de Baaij JH, Blanchard MG, Lavrijsen M, Leipziger J, Bindels RJ, Hoenderop JG (2014) P2X4 receptor regulation of transient receptor potential melastatin type 6 (TRPM6)  $\text{Mg}^{2+}$  channels. *Pflugers Arch* 466(10):1941–1952
  44. Demeuse P, Penner R, Fleig A (2006) TRPM7 channel is regulated by magnesium nucleotides via its kinase domain. *J Gen Physiol* 127(4):421–434
  45. Bai JP, Hausman E, Lionberger R, Zhang X (2012) Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium. *Mol Pharm* 9(12):3495–3505
  46. Xie Jia, Sun Baonan, Jianyang Du, Yang Wenzhong, Chen Hsiang-Chin, Overton Jeffrey D, Runnels Loren W, Yue Lixia (2011) Phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) controls magnesium gatekeeper TRPM6 activity. *Sci Rep* 1:146